Helius Medical Technologies Stock Earnings Reports

Key investor takeaways:

- Business & strategy: Solana Company is positioning as an APAC-focused institutional gateway to Solana with a three‑pillar commercial strategy: (1) bespoke advisory to institutions (targeting stablecoin payments and RWA tokenization), (2) validated infrastructure (“Pacific Backbone”) for institutional-grade validation/staking, and (3) an AI-powered compliance/operations platform to orchestrate partner activity. Management describes these as a self‑reinforcing flywheel and expects operational impact within the fiscal year.

- Financial results (Q1 2026): Revenue was $3.6M (primarily $3.4M staking revenue). Gross profit $3.4M. Reported net loss was $99.8M (loss per share $1.30) driven largely by a noncash unrealized loss on digital assets of ~$89.2M due to a ~33% SOL price decline. Operating expenses included $7.0M realized loss from strategic SOL sales.

- Treasury & staking performance: Average net staking yield was 6.9% in Q1 (outperforming the system average ~6.0% by ~90 bps). Staking rewards are auto‑restaked to compound returns. As of March 31, 2026 the company held ~193.8M USD of Solana across categories and $4.4M cash; as of May 12, 2026 it reported holding 2.37M SOL and a diluted share count of ~86.0M.

- Capital allocation & balance sheet moves: The company executed ~$3.5M of share repurchases in Q1 (year‑to‑date $5.0M) and completed an $8M strategic capital raise at $2.60/share in late April (reported as accretive to SOL per share). Management said they will pursue accretive capital actions and may prefer capital raises at current multiples rather than aggressive buybacks. They also completed divestiture/rationalization of cash‑burning legacy businesses (PoNS/medical device) in Q2, which they expect to improve results going forward.

- Execution & cadence: Pacific Backbone validator nodes (initially 3) are expected to be operational late June; management reports verbal commitments from third parties to delegate SOL but will provide more concrete guidance next quarter. Advisory traction: management says they are signing contracts with major institutions in APAC and expect those to generate material revenue this year. SG&A: management intends to keep cost growth disciplined and let revenue lead hiring; no board‑approved detailed run rate guidance was provided.

- Risks & investor considerations: The business remains highly correlated to SOL price (large unrealized losses when price falls). Many growth plans (third‑party delegations, advisory contracts, platform adoption) are at early stages and headline metrics (SOL per share, staking yield) are key performance indicators to watch. Capital allocation choices (raise vs buyback) will materially affect SOL per share and NAV dynamics.